TY - JOUR
T1 - Nifedipine blockade of ergonovine-lnduced coronary arterial spasm
T2 - Angiographic documentations
AU - Tiefenbrunn, Alan J.
AU - Sobel, Burton E.
AU - Gowda, Siddhesh
AU - Mcknight, Obert C.
AU - Ludbrook, Philip A.
N1 - Funding Information:
From the Cardiovascular Division, Department of Medicine and the Edward Mallinckrodt Institute of Radiology, Washington University School of Medicine, St . Louis, Missouri . This study was supported in part by the National Heart, Lung, and Blood Institute (Specialized Center of Research for Ischemic Heart Disease Grant HL 17646), National Institutes of Health, Bethesda, Maryland. Manuscript received January 13, 1981, accepted February 13,1981 .
PY - 1981/7
Y1 - 1981/7
N2 - To determine whether calcium-flux blockade with nifedipine blunts coronary vasospasm, four patients with angiographically demonstrable coronary arterial spasm in the absence of Significant fixed coronary arterial stenosis were evaluated with coronary arteriography before and after treatment with nifedipine. After initial coronary arteriography, ergonovine was administered in successive doses of 0.05, 0.1 and (when necessary) 0.2 mg intravenously at 3 minute intervals. Three patients had symptomatic high grade focal coronary arterial spasm with electrocardiographic changes, and the fourth exhibited asymptomatic 60 percent constriction of the left anterior descending coronary artery. A maximal ergonovine challenge was repeated 30 minutes later after each patient had been pretreated with a 20 mg sublingual dose of nifedipine. Under these conditions, no patient had chest pain or electrocardiographic changes. Furthermore, neither focal nor diffuse coronary arterial spasm was demonstrable angiographically after the second challenge. Thus, in each case, a single dose of nifedipine precluded the angiographie expression of ergonovine-provoked coronary arterial spasm.
AB - To determine whether calcium-flux blockade with nifedipine blunts coronary vasospasm, four patients with angiographically demonstrable coronary arterial spasm in the absence of Significant fixed coronary arterial stenosis were evaluated with coronary arteriography before and after treatment with nifedipine. After initial coronary arteriography, ergonovine was administered in successive doses of 0.05, 0.1 and (when necessary) 0.2 mg intravenously at 3 minute intervals. Three patients had symptomatic high grade focal coronary arterial spasm with electrocardiographic changes, and the fourth exhibited asymptomatic 60 percent constriction of the left anterior descending coronary artery. A maximal ergonovine challenge was repeated 30 minutes later after each patient had been pretreated with a 20 mg sublingual dose of nifedipine. Under these conditions, no patient had chest pain or electrocardiographic changes. Furthermore, neither focal nor diffuse coronary arterial spasm was demonstrable angiographically after the second challenge. Thus, in each case, a single dose of nifedipine precluded the angiographie expression of ergonovine-provoked coronary arterial spasm.
UR - http://www.scopus.com/inward/record.url?scp=0019511358&partnerID=8YFLogxK
U2 - 10.1016/0002-9149(81)90589-0
DO - 10.1016/0002-9149(81)90589-0
M3 - Article
C2 - 7246441
AN - SCOPUS:0019511358
SN - 0002-9149
VL - 48
SP - 184
EP - 187
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 1
ER -